No Prescription |
 |
 | ||
|
BETAGLIM Amaryl |
|
| ||
No Prescription » Prescription Drugs 3 » BETAGLIM Amaryl Glimepiride is an anti-diabetic drug (sulfonylurea-type) used along with a proper diet and exercise program to control high blood sugar. It is used in patients with type 2 diabetes (non-insulin-dependent diabetes). It works by stimulating the release of your body's natural insulin. Effectively controlling high blood sugar helps prevent heart disease strokes kidney disease blindness and circulation problems as well as sexual function problems (impotence).How to use Glimepiride OralTake this medication by mouth usually once daily with breakfast or the first main meal of the day. The dosage is based on your medical condition and response to therapy.Use this medication regularly in order to get the most benefit from it. To help you remember use it at the same time each day. Monitor blood glucose levels on a regular basis and share the results with your doctor. Buy BETAGLIM Amaryl and other Prescription Drugs 3 products online at Medstore. Buy Online at Medstore - Click Here!
About BETAGLIM Amaryl: Product Type: Prescription Drugs 3 BETAGLIM ( Amaryl Generic Glimepiride ) BETAGLIM (Amaryl Generic Glimepiride) Amaryl Generic Glimepiride 3mg Tabs 30 ( 3 x 10) 4mg Tabs Amaryl Generic Glimepiride BETAGLIM
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
